Vimian Group AB (publ) (STO:VIMIAN)

Market Cap	13.92B -33.5%
Revenue (ttm)	4.65B +19.5%
Net Income	348.26M +18,539.1%
EPS	0.66 +105,214.0%
Shares Out	529.26M
PE Ratio	39.63
Forward PE	21.60
Dividend	n/a
Ex-Dividend Date	n/a

Volume	403,102
Average Volume	202,728
Open	26.04
Previous Close	26.30
Day's Range	26.04 - 26.82
52-Week Range	26.00 - 47.30
Beta	1.42
RSI	31.19
Earnings Date	Feb 12, 2026

About Vimian Group AB

Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription treatments for preventive care and treatment of chronic conditions for companion animals under the Nextmune brand name; and molecular and immunodiagnostic solutions that are used by laboratories for veterinary specific applications with a focus on livestock and companion animal health markets under the I...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 1,200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VIMIAN

Financial Performance

In 2024, Vimian Group AB's revenue was 374.80 million, an increase of 12.99% compared to the previous year's 331.70 million. Earnings were 18.50 million, an increase of 88.78%.

Financial numbers in EUR